{"doc_id": "33129099", "type of study": "Therapy", "title": "", "abstract": "Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.\nAs an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure.\nHowever, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production.\nWe aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.\nForty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion.\nSubsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group.\nThe mRNA expression and cytokine secretion levels of IL-1\u03b2, IL-6, TNF-\u03b1 and IL-18 were assessed by Real-time PCR and ELISA, respectively.\nOur primary results indicated that the mRNA expression and cytokine secretion of IL-1\u03b2, IL-6, TNF-\u03b1, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group.\nAfter treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P\u00a0=\u00a00.0003, 0.0038, and 0.0001, respectively) and IL-1\u03b2 gene expression and secretion level in serum and supernatant (P\u00a0=\u00a00.0017, 0.0082, and 0.0041, respectively) was observed.\nHowever, IL-18 mRNA expression and TNF-\u03b1 concentration were not influenced by Nano-curcumin.\nNano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1\u03b2 and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.\nCopyright \u00a9 2020.\nPublished by Elsevier B.V.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 91}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 105}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 14}, {"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 38}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 23}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 154}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 198, "end": 206}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Nano-curcumin therapy , a promising method in modulating inflammatory cytokines in COVID-19 patients .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 91}], "Intervention": [{"term": "Nano-curcumin therapy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 21, "has_procedure": [{"text": "nano curcumin therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 21}], "has_relation": "N/A"}], "Outcome": [{"term": "inflammatory cytokines", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 79}], "Observation": [{"term": "promising", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 35}, {"term": "modulating", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 56}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "As an ongoing worldwide health issue , Coronavirus disease 2019 ( COVID-19 ) has been causing serious complications , including pneumonia , acute respiratory distress syndrome ( ARDS ) , and multi-organ failure .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "However , there is no decisive treatment approach available for this disorder , which is primarily attributed to the large amount of inflammatory cytokine production .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 105}], "Intervention": [{"term": "Nano-curcumin", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 49, "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "modulation of inflammatory cytokines", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 93}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHOD", "Text": "Forty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 14}, {"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 38}], "Intervention": [], "Outcome": [{"term": "inflammatory cytokine expression", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 113}, {"term": "secretion", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 127}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHOD", "Text": "Subsequently , COVID-19 patients were divided into two groups : 20 patients receiving Nano-curcumin and 20 patients as the placebo group .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 23}], "Intervention": [{"term": "Nano-curcumin", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 99, "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHOD", "Text": "The mRNA expression and cytokine secretion levels of IL-1\u03b2 , IL-6 , TNF-\u03b1 and IL-18 were assessed by Real-time PCR and ELISA , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "mRNA expression", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 19}, {"term": "cytokine secretion levels of IL-1\u03b2", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 58}, {"term": "IL-6", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 65}, {"term": "TNF-\u03b1", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 73}, {"term": "IL-18", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 83}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULT", "Text": "Our primary results indicated that the mRNA expression and cytokine secretion of IL-1\u03b2 , IL-6 , TNF-\u03b1 , and IL-18 were increased significantly in COVID-19 patients compared with healthy control group .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 154}], "Intervention": [], "Outcome": [{"term": "mRNA expression", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 54}, {"term": "cytokine secretion of IL-1\u03b2", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 86}, {"term": "IL-6", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 93}, {"term": "TNF-\u03b1", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 101}, {"term": "IL-18", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 113}], "Observation": [{"term": "increased significantly", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 142}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULT", "Text": "After treatment with Nano-curcumin , a significant decrease in IL-6 expression and secretion in serum and in supernatant ( P = 0.0003 , 0.0038 , and 0.0001 , respectively ) and IL-1\u03b2 gene expression and secretion level in serum and supernatant ( P = 0.0017 , 0.0082 , and 0.0041 , respectively ) was observed .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Nano-curcumin", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 34, "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "IL-6 expression", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 78}, {"term": "secretion", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 92}, {"term": "IL-1\u03b2 gene expression", "negation": "affirmed", "UMLS": {}, "start": 177, "end": 198}, {"term": "secretion level", "negation": "affirmed", "UMLS": {}, "start": 203, "end": 218}], "Observation": [{"term": "significant decrease", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 59}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "significant decrease", "Outcome": "IL-6 expression", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "significant decrease", "Outcome": "secretion", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "significant decrease", "Outcome": "IL-1\u03b2 gene expression", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "significant decrease", "Outcome": "secretion level", "Count": ""}]}, {"Section": "RESULT", "Text": "However , IL-18 mRNA expression and TNF-\u03b1 concentration were not influenced by Nano-curcumin .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "IL-18 mRNA expression", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 31}, {"term": "TNF-\u03b1 concentration", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 55}], "Observation": [{"term": "influenced", "negation": "negated", "UMLS": {}, "start": 65, "end": 75}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Nano-curcumin , as an anti-inflammatory herbal based agent , may be able to modulate the increased rate of inflammatory cytokines especially IL-1\u03b2 and IL-6 mRNA expression and cytokine secretion in COVID-19 patients , which may cause an improvement in clinical manifestation and overall recovery .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 198, "end": 206}], "Intervention": [{"term": "Nano-curcumin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13, "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "rate of inflammatory cytokines", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 129}, {"term": "IL-1\u03b2", "negation": "affirmed", "UMLS": {}, "start": 141, "end": 146}, {"term": "IL-6 mRNA expression", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 171}, {"term": "cytokine secretion", "negation": "affirmed", "UMLS": {}, "start": 176, "end": 194}, {"term": "clinical manifestation", "negation": "affirmed", "UMLS": {}, "start": 252, "end": 274}], "Observation": [{"term": "modulate", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 84}, {"term": "increased", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 98}, {"term": "improvement", "negation": "affirmed", "UMLS": {}, "start": 237, "end": 248}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "modulate", "Outcome": "IL-1\u03b2", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "modulate", "Outcome": "IL-6 mRNA expression", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "modulate", "Outcome": "cytokine secretion", "Count": ""}, {"Intervention": {"term": "Nano-curcumin", "has_chemical": [{"text": "nano curcumin", "maps_to": "C0010467:curcumin", "start": 0, "end": 13}], "has_relation": "N/A"}, "Observation": "improvement", "Outcome": "clinical manifestation", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier B.V .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}